These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35570245)

  • 21. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
    Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
    Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T
    Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
    Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.
    Zhao F; Mancuso A; Bui TV; Tong X; Gruber JJ; Swider CR; Sanchez PV; Lum JJ; Sayed N; Melo JV; Perl AE; Carroll M; Tuttle SW; Thompson CB
    Oncogene; 2010 May; 29(20):2962-72. PubMed ID: 20228846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M
    Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia.
    Aranda-Tavío H; Recio C; Martín-Acosta P; Guerra-Rodríguez M; Brito-Casillas Y; Blanco R; Junco V; León J; Montero JC; Gandullo-Sánchez L; McNaughton-Smith G; Zapata JM; Pandiella A; Amesty A; Estévez-Braun A; Fernández-Pérez L; Guerra B
    Biomed Pharmacother; 2021 Dec; 144():112330. PubMed ID: 34673425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors.
    Danisz K; Blasiak J
    Acta Biochim Pol; 2013; 60(4):503-14. PubMed ID: 24273759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
    Yandim MK; Ceylan C; Elmas E; Baran Y
    Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
    Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.
    Balabanov S; Gontarewicz A; Keller G; Raddrizzani L; Braig M; Bosotti R; Moll J; Jost E; Barett C; Rohe I; Bokemeyer C; Holyoake TL; Brümmendorf TH
    PLoS One; 2011 Apr; 6(4):e19164. PubMed ID: 21541334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
    Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
    Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
    Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-κB signaling activation.
    Yang T; Sim KY; Ko GH; Ahn JS; Kim HJ; Park SG
    J Exp Clin Cancer Res; 2022 Mar; 41(1):82. PubMed ID: 35241148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.
    Bellodi C; Lidonnici MR; Hamilton A; Helgason GV; Soliera AR; Ronchetti M; Galavotti S; Young KW; Selmi T; Yacobi R; Van Etten RA; Donato N; Hunter A; Dinsdale D; Tirrò E; Vigneri P; Nicotera P; Dyer MJ; Holyoake T; Salomoni P; Calabretta B
    J Clin Invest; 2009 May; 119(5):1109-23. PubMed ID: 19363292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alterations in Sialylation Patterns are Significantly Associated with Imatinib Mesylate Resistance in Chronic Myeloid Leukemia.
    Patel KD; De M; Jethva DD; Rathod BS; Patel PS
    Arch Med Res; 2022 Jan; 53(1):51-58. PubMed ID: 34275666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.
    Matsuda Y; Yamauchi T; Hosono N; Uzui K; Negoro E; Morinaga K; Nishi R; Yoshida A; Kimura S; Maekawa T; Ueda T
    Cancer Sci; 2016 Jul; 107(7):1029-38. PubMed ID: 27166836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia.
    Roskoski R
    Pharmacol Res; 2022 Apr; 178():106156. PubMed ID: 35257901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells.
    Ma D; Fang Q; Wang P; Gao R; Wu W; Lu T; Cao L; Hu X; Wang J
    J Biol Chem; 2015 May; 290(20):12558-71. PubMed ID: 25802333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imatinib-mesylate enhances the maintenance of chronic myeloid leukemia stem cell potential in the absence of glucose.
    Bono S; Dello Sbarba P; Lulli M
    Stem Cell Res; 2018 Apr; 28():33-38. PubMed ID: 29414416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients.
    Elias MH; Azlan H; Sulong S; Baba AA; Ankathil R
    Cancer Rep (Hoboken); 2018 Aug; 1(2):e1111. PubMed ID: 32721103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.